Method for inhibiting proliferation of cancer cells

Patent metadata

Field	Value
Publication number	US-12377058-B1
Application number	US-202418649785-A
Country	US
Kind code	B1
Filing date	Apr 29, 2024
Priority date	Apr 29, 2024
Publication date	Aug 5, 2025
Grant date	Aug 5, 2025

Abstract

A method for inhibiting proliferation of cancer cells includes contacting the cancer cells with a cytotoxic effective amount of an anticancer compound of Formula (I);

where R1 to R8 are each independently selected from a group consisting of a hydrogen atom, a halogen atom, and an optionally substituted alkyl. The anticancer compound exhibits an IC 50 of from 2 micrograms per milliliters (μg/ml) to 10 μg/ml for inhibiting the proliferation and inducing the apoptosis of cancer cells.

First claim

The invention claimed is:

1. A method for inhibiting proliferation of cancer cells, comprising:
contacting the cancer cells with a cytotoxic effective amount of an anticancer compound of Formula (I);

wherein R 1 to R 8 are each independently selected from a group consisting of a hydrogen atom, a halogen atom, and an optionally substituted alkyl; and
wherein the anticancer compound exhibits an IC 50 of from 2 to 10 μg/ml for inhibiting the proliferation and inducing the apoptosis of cancer cells.

2. The method of claim 1 , wherein the anticancer compound has a Formula (II)

3. The method of claim 1 , wherein the cancer cells comprise one or more cancer stem cells selected from a group consisting of a breast cancer stem cell, a lung cancer stem cell, a prostate cancer stem cell, an osteosarcoma cancer stem cell, an ovarian cancer stem cell, a colon carcinoma stem cell, and a melanoma stem cell.

4. The method of claim 1 , wherein the cancer cells are A549 lung cancer stem cells, and wherein the method has an IC 50 of about 5-7.5 μg/ml.

5. The method of claim 1 , wherein the cancer cells are PC3 cancer stem cells, and wherein the method has an IC 50 of about 4-6.5 μg/ml.

6. The method of claim 1 , wherein the cancer cells are FaDu cancer stem cells, and wherein the method has an IC 50 of about 5-7 μg/ml.

7. The method of claim 1 , wherein the cancer cells are triple-MDA-MB-468 cancer stem cells, and wherein the method has an IC 50 of about 5-7 μg/ml.

8. The method of claim 1 , wherein the cancer cells are HeLa cancer stem cells, and wherein the method has an IC 50 of about 5.5-7 μg/ml.

9. The method of claim 2 , wherein the contacting the cancer cells with the anticancer compound of Formula (II) is in the presence of doxorubicin, and wherein the method exhibits an improved inhibition efficiency at a reduced cytotoxic effective amount as compared to the use of anticancer compound in the absence of doxorubicin.

10. The method of claim 1 , further comprising preparing the anticancer compound of Formula (I) by:
mixing a phenol compound, a benzaldehyde compound, and an inorganic base in a solvent to form a mixture; and
heating the mixture at a temperature of from 120 to 160° C.;
wherein a molar ratio of the phenol compound to the benzaldehyde compound is in a range of 1:2 to 2:1.

11. The method of claim 10 , wherein the phenol compound is 4-pentoxyphenol.

12. The method of claim 10 , wherein the benzaldehyde compound is 4-fluorobenzaldehyde.

13. The method of claim 10 , wherein the inorganic base is at least one of potassium carbonate, and sodium carbonate.

14. The method of claim 10 , wherein the solvent is dimethyl sulfoxide (DMSO).

15. The method of claim 10 , wherein a molar ratio of the phenol compound to the inorganic base is in a range of 1:1 to 1:2, and wherein a molar ratio of the benzaldehyde compound to the inorganic base is in a range of 1:1 to 1:2.

Assignees

• Imam Mohammad Ibn Saud Islamic Univ

Inventors

• Yousef Tarek Ahmed
• Shaaban Saad
• Ba-Ghazal Hussein
• Sharaky Marwa
• Al-Karmalawy Ahmed A

Classifications

• G01N33/5758 Primary

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/09 Primary

  having two or more such linkages · CPC title

• G01N33/57484

  Physics · mapped topic